Taiho Ventures has supplied a $10m extension for Caltech spinout Axial Biotherapeutics’ series B, bringing the total to $35m.
Axial Biotherapeutics, a US-based biotechnology developer spun out of California Institute of Technology (Caltech), boosted its series B round to $35m on Thursday following a $10m extension provided by pharmaceutical firm Taiho.
Taiho supplied the money through its corporate venturing arm, Taiho Ventures. Axial closed an initial $25m tranche in February 2019 led by Health for Life Capital, a fund managed by Seventure Partners, with participation from healthcare provider Heritage Medical Systems.
Investment management firms Longwood Fund…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
